Application of Remimazolam Combined with Butorphanol in Painless Gastrointestinal Endoscopy for Obese Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500104455

Enrollment

Unknown

Registered

2025-06-17

Start date

2025-07-01

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Gastrointestinal Endoscopy

Interventions

Group Remimazolam:Remimazolam sedation combined with butorphanol

Group Remimazolam And Propofol :Remimazolam and Propofol sedation combined with butorphanol

Group Propofol :Propofol sedation combined with butorphanol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age 18-65 years old; 2. ASA physical status I-III; 3. BMI >=18.5 kg/m2; 4.Agree and sign the informed consent file.

Exclusion criteria

Exclusion criteria: 1.Modified Mallampati Classification of level IV; 2.Patients with contraindications to the drugs; 3. Patients planning trachea cannula,complex gastrointestinal endoscopy procedures such as endoscopic mucosal dissection, or examination time more than 1 hour; 4. A history of drug or alcohol abuse; 5. Mental disorders, neurological diseases, auditory or visual impairments.

Design outcomes

Primary

Measure	Time frame
level of sedation recovery;incidence of adverse events;	—

Secondary

Measure	Time frame
effectiveness during the insertion of gastroscope;Changes of vital signs;	—

Countries

China

Contacts

Public ContactZhiyong Gao

363 hospital of Genertec Medical

19828477386@163.com+86 136 4519 4981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026